Innovative Antibody Pipeline

United BioPharma (UBP) is dedicated to the development and commercialization of proprietary monoclonal antibodies with significant impact to patients. We have established a set of advanced antibody platform technologies in our state-of-the-art Research and Development and Manufacturing facilities based in Hsinchu, Taiwan. Our cGMP manufacturing plant, considered largest in Taiwan, is fully equipped with high-end sophisticated instruments for commercial scale manufacturing.

Our Integrated Technology Platform

UBP possesses high value technology platform: A fully integrated monoclonal antibody (mAb) drug development technology which enables us to generate stable, high productivity, and serum free clones for industrial scale mAb production. Our competitive cell and protein process development, characterization, analytical and formulation method allow us to develop high titer, robust and scalable cell culture and protein fermentation resulting in optimized-yield, high quality and robust purification process for our produced antibodies.

News and Events

News Releases

  • 2022/05/26
    United BioPharma Receives IND Approval from TFDA for A Phase 2 Study of UB-221 in Adults with Chronic Spontaneous Urticaria
  • 2021/10/18
    United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621
  • 2021/08/18
    United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure

8th Annual Biologics World Taiwan 2020 - Dr. Lynn

UBP Huko Building Intro.

Shareholder Briefcase